Evidence map›Paper›PMID 37717172›Full record

ArticleG3 (Bethesda, Md.)2023

CRISPR screen identifies CEBPB as contributor to dyskeratosis congenita fibroblast senescence via augmented inflammatory gene response.

Erik R Westin, Alireza Khodadadi-Jamayran, Linh K Pham, Moon Ley Tung, Frederick D Goldman

Open access · goldAbstract read
In one paragraph

Article in G3 (Bethesda, Md.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.9field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. IL-1βJournal of neuroinflammation · 2025
    Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 1 country.

Erik R WestinDepartment of Pediatrics, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Alireza Khodadadi-JamayranGenome Technology Center, Applied Bioinformatics Laboratories, NYU Langone Medical Center, New York, NY 10016, USA.
Linh K PhamDepartment of Pediatrics, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
Moon Ley TungStead Family Department of Pediatrics, Division of Medical Genetics and Genomics, University of Iowa, Iowa City, IA 52242, USA.
Frederick D GoldmanDepartment of Pediatrics, Division of Hematology Oncology, University of Alabama at Birmingham, Birmingham, AL 35294, USA.
University of Alabama at Birmingham · USNYU Langone Health · USUniversity of Iowa · US

Funding

XRAY CRYSTALLOGRAPHYP30CA013148 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Omer Jamy · 1985 to 2026
$165.9M
ROS Modulation of Innate and Adaptive Immunity in RAP30AR048311 · NIAMS · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI MOUNTZ, JOHN D · 2001 to 2017
$9.5M
NCI NIH HHS P30 CA013148NIAMS NIH HHS P30 AR048311
6 · The paper itself

Abstract

Aging is the consequence of intra- and extracellular events that promote cellular senescence. Dyskeratosis congenita (DC) is an example of a premature aging disorder caused by underlying telomere/telomerase-related mutations. Cells from these patients offer an opportunity to study telomere-related aging and senescence. Our previous work has found that telomere shortening stimulates DNA damage responses (DDRs) and increases reactive oxygen species (ROS), thereby promoting entry into senescence. This work also found that telomere elongation via TERT expression, the catalytic component of the telomere-elongating enzyme telomerase, or p53 shRNA could decrease ROS by disrupting this telomere-DDR-ROS pathway. To further characterize this pathway, we performed a CRISPR/Cas9 knockout screen to identify genes that extend life span in DC cells. Of the cellular clones isolated due to increased life span, 34% had a guide RNA (gRNA) targeting CEBPB, while gRNAs targeting WSB1, MED28, and p73 were observed multiple times. CEBPB is a transcription factor associated with activation of proinflammatory response genes suggesting that inflammation may be present in DC cells. The inflammatory response was investigated using RNA sequencing to compare DC and control cells. Expression of inflammatory genes was found to be significantly elevated (P < 0.0001) in addition to a key subset of these inflammation-related genes [IL1B, IL6, IL8, IL12A, CXCL1 (GROa), CXCL2 (GROb), and CXCL5]. which are regulated by CEBPB. Exogenous TERT expression led to downregulation of RNA/protein CEBPB expression and the inflammatory response genes suggesting a telomere length-dependent mechanism to regulate CEBPB. Furthermore, unlike exogenous TERT and p53 shRNA, CEBPB shRNA did not significantly decrease ROS suggesting that CEBPB's contribution in DC cells' senescence is ROS independent. Our findings demonstrate a key role for CEBPB in engaging senescence by mobilizing an inflammatory response within DC cells.

Indexed as

Dyskeratosis CongenitaTelomeraseCCAAT-Enhancer-Binding Protein-betaFibroblastsHumansInflammationMediator ComplexMutationReactive Oxygen SpeciesRNA, Small InterferingTelomereTumor Suppressor Protein p53CCAAT-Enhancer-Binding Protein-betaCEBPB protein, humanMED28 protein, humanMediator ComplexReactive Oxygen SpeciesRNA, Small InterferingTelomeraseTumor Suppressor Protein p53CEBPBCRISPRDyskeratosis congenitahuman primary fibroblastsinflammatory responseMED28oxidative stressp73telomereWSB1

Identifiers

PMID37717172
PMCPMC10627266
OpenAlexW4386809379

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.